Market capitalization | $1.01b |
Enterprise Value | $767.88m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.71 |
P/S ratio (TTM) P/S ratio | 4.89 |
P/B ratio (TTM) P/B ratio | 2.78 |
Revenue growth (TTM) Revenue growth | 29.35% |
Revenue (TTM) Revenue | $207.11m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -78 -78 |
28%
28%
|
|
Depreciation and Amortization | 12 12 |
330%
330%
|
|
Stock Compensation | 45 45 |
40%
40%
|
|
Operating Cash Flow | -33 -33 |
58%
58%
|
|
Investments | 0.72 0.72 |
148%
148%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -34 -34 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Head office | Canada |
CEO | Peter Greenleaf |
Employees | 300 |
Founded | 1993 |
Website | www.auriniapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.